Bayesian Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bayesian Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Buy	+19,200	New	+$1.1M	0.71%	37
2025 Q4	–	Sell	-25,500	Closed	-$1.15M	–	170
2025 Q3	$1.15M	Buy	25,500 +21,127	+483%	+$987K	0.23%	133
2025 Q2	$202K	Buy	+4,373	New	+$215K	0.03%	459
2024 Q4	–	Sell	-18,200	Closed	-$942K	–	704
2024 Q3	$942K	Buy	18,200 +6,300	+53%	+$296K	0.11%	250
2024 Q2	$494K	Buy	+11,900	New	+$532K	0.06%	373
2024 Q1	–	Sell	-104,800	Closed	-$5.38M	–	793
2023 Q4	$5.38M	Buy	+104,800	New	+$5.5M	0.57%	28
2021 Q4	–	Sell	-17,597	Closed	-$1.04M	–	384
2021 Q3	$1.04M	Buy	17,597 +3,677	+26%	+$242K	0.3%	85
2021 Q2	$930K	Sell	13,920 -44,270	-76%	-$2.89M	0.24%	109
2021 Q1	$3.67M	Buy	58,190 +4,790	+9%	+$298K	0.85%	18
2020 Q4	$3.31M	Buy	53,400 +35,000	+190%	+$2.15M	0.87%	15
2020 Q3	$1.11M	Sell	18,400 -5,600	-23%	-$337K	0.27%	94
2020 Q2	$1.41M	Buy	+24,000	New	+$1.44M	0.31%	78
2019 Q2	–	Sell	-57,800	Closed	-$2.76M	–	520
2019 Q1	$2.76M	Buy	+57,800	New	+$2.88M	0.53%	41
2018 Q2	–	Sell	-26,100	Closed	-$1.65M	–	600
2018 Q1	$1.65M	Buy	+26,100	New	+$1.68M	0.42%	40
2017 Q3	–	Sell	-29,088	Closed	-$1.62M	–	483
2017 Q2	$1.62M	Buy	+29,088	New	+$1.58M	0.6%	30
2017 Q1	–	Sell	-29,286	Closed	-$1.71M	–	421
2016 Q4	$1.71M	Buy	29,286 +25,486	+671%	+$1.39M	0.42%	38
2016 Q3	$205K	Buy	+3,800	New	+$244K	0.13%	284
2016 Q2	–	Sell	-4,194	Closed	-$268K	–	405
2016 Q1	$268K	Buy	+4,194	New	+$264K	0.25%	188

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bayesian Capital Management's BMY Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 19,200 shares worth $1.11M. The stake represents 0.71% of the portfolio and ranks #37 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in BMY as recently as Q3 2025.

Bayesian Capital Management first reported a position in BMY in Q1 2016 and has held it in 18 quarters since. The position peaked at $5.38M in Q4 2023. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Bayesian Capital Management held 19,200 shares of Bristol-Myers Squibb worth $1.11M as of Q2 2026.
Bristol-Myers Squibb was a new Bayesian Capital Management position in Q2 2026.
Bristol-Myers Squibb made up 0.71% of Bayesian Capital Management's portfolio in Q2 2026, its #37 holding.
Bayesian Capital Management first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 18 quarters since.
Bayesian Capital Management's Bristol-Myers Squibb position peaked at $5.38M in Q4 2023.
2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.